N-[3-[(2-benzthiazolyl)methoxy]phenyl]pyrrolidin-2-on-4-carboxylic acid, methyl ester | 101626-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-[3-[(2-benzthiazolyl)methoxy]phenyl]pyrrolidin-2-on-4-carboxylic acid, methyl ester
• 英文别名: WY-46543；1-[3-(Benzothiazol-2-ylmethoxy)-phenyl]-5-oxo-pyrrolidine-3-carboxylic acid methyl ester；methyl 1-[3-(1,3-benzothiazol-2-ylmethoxy)phenyl]-5-oxopyrrolidine-3-carboxylate
• CAS: 101626-20-4
• 化学式: C₂₀H₁₈N₂O₄S
• 分子量: 382.44
• InChiKey: VGXUJYGWPFXFQH-UHFFFAOYSA-N

物化性质

• 沸点：
  629.5±55.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  97
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  衣康酸 在 sodium carbonate 、 caesium carbonate 、 对甲苯磺酸 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 96.08h， 生成 N-[3-[(2-benzthiazolyl)methoxy]phenyl]pyrrolidin-2-on-4-carboxylic acid, methyl ester
  参考文献：
  名称：

  白三烯D4拮抗剂和5-脂氧合酶抑制剂。苯并杂环的[（甲氧基苯基）氨基]氧代链烷酸酯的合成。

  摘要：

  已经制备了一系列新颖的苯并杂环[（甲氧基苯基）氨基]氧代链烷酸酯。这些化合物在体外试验中作为大鼠多形核白细胞5-脂氧合酶（LO）的抑制剂，以及白三烯D4（LTD4）和卵清蛋白（OA）诱导的豚鼠（GP）支气管痉挛的抑制剂。通常，对于含苯并噻唑的类似物（对苯并噻唑大于苯并咪唑比对苯并恶唑，苯并呋喃要大得多）对5-LO，LTD4和OA的抑制活性最广。最有效的5-LO抑制剂4-[[[3-（2-苯并噻唑基甲氧基）-苯基]羟基氨基] -4-氧代丁酸甲酯（7）的IC50为0.36 microM。但是，化合物7与OA相比没有活性。体内最有效的化合物4-[[[3-[（1-甲基-2-苯并咪唑基）甲氧基]苯基]-氨基] -4-氧代丁酸甲酯4，在十二指肠内以50 mg / kg的浓度分别抑制LTD4-和OA诱导的支气管痉挛分别达到83％和60％。在Ames分析中使用五种细菌菌株（TA1535，TA1537，TA1

  DOI：

  10.1021/jm00385a024

文献信息

• MUSSER, J. H.
  作者：MUSSER, J. H.

  DOI：——

  日期：——
• NOGO RECEPTOR FUNCTIONAL MOTIFS, PEPTIDE MIMETICS, AND MUTATED FUNCTIONAL MOTIFS RELATED THERETO, AND METHODS OF USING THE SAME
  申请人：Wood Andrew

  公开号：US20080027001A1

  公开（公告）日：2008-01-31

  The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) (e.g., the binding pocket on the side surface of NgR1, functional motifs comprising the amino acid sequence of FRG, etc.) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, GT1 b , an antibody to Nogo receptor, an antibody to GT1 b , an antibody to p75 neurotrophin receptor, and an antibody to Lingo-1, etc. The invention also provides antibodies to the mimetic peptide antagonists. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for treatments requiring axonal regeneration, i.e., reversal of the effects of NgR1 ligand binding to the NgR1 (i.e., producing inhibition of axonal growth). The present invention also is directed to novel methods for treating disorders arising from inhibition of axonal growth mediated by the binding of NgR1 ligands to the NgR1. Further, the invention is directed to methods of treating a subject with a neurodegenerative disorder, including, but not limited to, Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, multiple sclerosis, multiple system atrophy, corticobasal degeneration, Huntington's disease, dementia with Lewy bodies, spinocerebellar ataxia, stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, epilepsy, and senile dementia, comprising, e.g., antagonizing NgR1.